Asset Details
Do you wish to reserve the book?
Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
Do you wish to request the book?
Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Cost‐effectiveness of ipilimumab versus high‐dose interferon as an adjuvant therapy in resected high‐risk melanoma
2021
Overview
Background Adjuvant ipilimumab was found to improve the overall survival and reduce toxicity compared to high‐dose interferon (HDI) in patients with resected, high‐risk melanoma. However, the cost of ipilimumab is substantially higher than HDI. This study evaluates the cost‐effectiveness of ipilimumab as an adjuvant treatment in melanoma from a healthcare perspective. Methods We designed a Markov model simulating resected, high‐risk melanoma patients receiving either ipilimumab or HDI. Transition probabilities, including risks of survival, disease progression, and toxicity, were ascertained from clinical trial data. Costs and quality of life measurements (health utilities) were extracted from the literature. Incremental cost‐effectiveness ratios (ICERs), defined as incremental costs divided by incremental quality‐adjusted life‐years (QALYs), assessed cost‐effectiveness. ICERs < $100,000/QALY were deemed cost‐effective. We measured model uncertainty with one‐way and probabilistic sensitivity analyses. Results In our base case model, ipilimumab increased costs by $ 107,100 and increased effectiveness by 0.43 QALY, yielding an ICER of$392,600/QALY. Our model was moderately sensitive to the costs of ipilimumab, though the cost of ipilimumab would need to decrease by 44% for ipilimumab to become cost‐effective compared to HDI. The model was not sensitive to survival, toxicity, or other costs. Probabilistic sensitivity analysis showed that HDI would remain the cost‐effective treatment option 96.2% of the time at a willingness‐to‐pay threshold of $ 100,000/QALY. Conclusions Adjuvant ipilimumab increases the survival and decreases the toxicity compared to HDI in resected, high‐risk melanoma patients, though this would not be considered cost‐effective due to the high price of ipilimumab. Ipilimumab is not a cost‐effective adjuvant treatment option compared with high‐dose interferon for resected, high‐risk melanoma. The cost of ipilimumab would have to decrease substantially to reach cost‐effectiveness.
Publisher
John Wiley & Sons, Inc,John Wiley and Sons Inc,Wiley
Subject
/ Antineoplastic Agents, Immunological - pharmacology
/ Antineoplastic Agents, Immunological - therapeutic use
/ Antineoplastic Combined Chemotherapy Protocols - pharmacology
/ Antineoplastic Combined Chemotherapy Protocols - therapeutic use
/ Chemotherapy, Adjuvant - methods
/ Cost-Benefit Analysis - methods
/ Female
/ Humans
/ Interferons - therapeutic use
/ Ipilimumab - therapeutic use
/ Male
/ Melanoma
/ Patients
/ Survival
/ Toxicity
